Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 6872046, 9 pages
https://doi.org/10.1155/2017/6872046
Clinical Study

Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step

1Tissue Typing Laboratory, Charité Universitätsmedizin Berlin, Berlin, Germany
2Department of Nephrology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
3University Tissue Bank, Institute of Transfusion Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany

Correspondence should be addressed to Nils Lachmann; ed.etirahc@nnamhcal.slin

Received 23 September 2016; Revised 17 December 2016; Accepted 15 January 2017; Published 31 January 2017

Academic Editor: Mepur H. Ravindranath

Copyright © 2017 Nils Lachmann et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. I. Terasaki and J. Cai, “Humoral theory of transplantation: further evidence,” Current Opinion in Immunology, vol. 17, no. 5, pp. 541–545, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Lachmann, P. I. Terasaki, K. Budde et al., “Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts,” Transplantation, vol. 87, no. 10, pp. 1505–1513, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Sellarés, D. G. De Freitas, M. Mengel et al., “Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence,” American Journal of Transplantation, vol. 12, no. 2, pp. 388–399, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. S. A. Burton, N. Amir, A. Asbury, A. Lange, and K. L. Hardinger, “Treatment of antibody-mediated rejection in renal transplant patients: a clinical practice survey,” Clinical Transplantation, vol. 29, no. 2, pp. 118–123, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. D. M. Roberts, S. H. Jiang, and S. J. Chadban, “The treatment of acute antibody-mediated rejection in kidney transplant recipients—a systematic review,” Transplantation, vol. 94, no. 8, pp. 775–783, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. M. J. Everly and P. I. Terasaki, “The state of therapy for removal of alloantibody producing plasma cells in transplantation,” Seminars in Immunology, vol. 24, no. 2, pp. 143–147, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Waiser, K. Budde, M. Schütz et al., “Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection,” Nephrology Dialysis Transplantation, vol. 27, no. 3, pp. 1246–1251, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. I. Schwab and F. Nimmerjahn, “Intravenous immunoglobulin therapy: how does IgG modulate the immune system?” Nature Reviews Immunology, vol. 13, no. 3, pp. 176–189, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Kaneko, F. Nimmerjahn, and J. V. Ravetch, “Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation,” Science, vol. 313, no. 5787, pp. 670–673, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Sis, M. Mengel, M. Haas et al., “Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups,” American Journal of Transplantation, vol. 10, no. 3, pp. 464–471, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. S. Levey, L. A. Stevens, C. H. Schmid et al., “A new equation to estimate glomerular filtration rate,” Annals of Internal Medicine, vol. 150, no. 9, pp. 604–612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Schröter, G. Lindemann, and L. Fritsche, “TBase2—a web-based electronic patient record,” Fundamenta Informaticae, vol. 43, no. 1-4, pp. 343–353, 2000. View at Google Scholar · View at Scopus
  13. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
  14. L. C. Racusen, R. B. Colvin, K. Solez et al., “Antibody-mediated rejection criteria—an addition to the Banff '97 classification of renal allograft rejection,” American Journal of Transplantation, vol. 3, no. 6, pp. 708–714, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Sautenet, G. Blancho, M. Büchler et al., “One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial,” Transplantation, vol. 100, no. 2, pp. 391–399, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. M. J. Everly, L. M. Rebellato, M. Ozawa et al., “Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection,” Transplantation, vol. 89, no. 8, pp. 962–967, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Steiner, F. Aigner, H. Kathrein, C. Huber, and R. Margreiter, “Value of preventive immunoglobulin administration in cadaveric kidney transplantation,” Wiener Klinische Wochenschrift, vol. 96, no. 7, pp. 264–266, 1984. View at Google Scholar
  18. M.-N. Peraldi, K. Akposso, J.-P. Haymann et al., “Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation,” Transplantation, vol. 62, no. 11, pp. 1670–1673, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. S. C. Jordan, A. W. Quartel, L. S. C. Czer et al., “Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral reaction in renal and cardiac allograft recipients and potential mechanism of action,” Transplantation, vol. 66, no. 6, pp. 800–808, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. D. H. Casadei, M. C. Rial, G. Opelz et al., “A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection,” Transplantation, vol. 71, no. 1, pp. 53–58, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. P. P. W. Luke, V. P. Scantlebury, M. L. Jordan et al., “Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients,” Transplantation, vol. 72, no. 3, pp. 419–422, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Lefaucheur, D. Nochy, J. Andrade et al., “Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection,” American Journal of Transplantation, vol. 9, no. 5, pp. 1099–1107, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. J. E. Cooper, J. Gralla, P. Klem, L. Chan, and A. C. Wiseman, “High dose intravenous immunoglobulin therapy for donor-specific antibodies in kidney transplant recipients with acute and chronic graft dysfunction,” Transplantation, vol. 97, no. 12, pp. 1253–1259, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Glotz, J.-P. Haymann, N. Sansonetti et al., “Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg): a potential tool for transplantation of immunized patients,” Transplantation, vol. 56, no. 2, pp. 335–337, 1993. View at Publisher · View at Google Scholar · View at Scopus
  25. S. C. Jordan, D. Tyan, D. Stablein et al., “Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial,” Journal of the American Society of Nephrology, vol. 15, no. 12, pp. 3256–3262, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. M. D. Stegall, J. Gloor, J. L. Winters, S. B. Moore, and S. DeGoey, “A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody,” American Journal of Transplantation, vol. 6, no. 2, pp. 346–351, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. A. A. Vo, M. Lukovsky, M. Toyoda et al., “Rituximab and intravenous immune globulin for desensitization during renal transplantation,” The New England Journal of Medicine, vol. 359, no. 3, pp. 242–251, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. A. A. Vo, J. Choi, K. Cisneros et al., “Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients,” Transplantation, vol. 98, no. 3, pp. 312–319, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Liefeldt, S. Brakemeier, P. Glander et al., “Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation,” American Journal of Transplantation, vol. 12, no. 5, pp. 1192–1198, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Billing, S. Rieger, C. Süsal et al., “IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up,” Transplant International, vol. 25, no. 11, pp. 1165–1173, 2012. View at Publisher · View at Google Scholar · View at Scopus